TITLE

Temsirolimus

PUB. DATE
June 2014
SOURCE
Reactions Weekly;Jun2014, Vol. 1507 Issue 1, p29
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
An abstract of the article "Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors," by S. Weikert and colleagues is presented.
ACCESSION #
96839619

 

Related Articles

  • EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma. Davis, I. D.; Long, A.; Yip, S.; Espinoza, D.; Thompson, J. F.; Kichenadasse, G.; Harrison, M.; Lowenthal, R. M.; Pavlakis, N.; Azad, A.; Kannourakis, G.; Steer, C.; Goldstein, D.; Shapiro, J.; Harvie, R.; Jovanovic, L.; Hudson, A. L.; Nelson, C. C.; Stockler, M. R.; Martin, A. // Annals of Oncology;Jun2015, Vol. 26 Issue 6, p1118 

    Background: We hypothesised that alternating inhibitors of the vascular endothelial growth factor receptor (VEGFR) and mammalian target of rapamycin pathways would delay the development of resistance in advanced renal cell carcinoma (aRCC). Patients and methods: A single-arm, two-stage,...

  • Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor. Park, Inkeun; Lee, Jae-Lyun; Ahn, Jin-Hee; Lee, Dae-Ho; Lee, Kyoo-Hyung; You, Dalsan; Jeong, In; Song, Cheryn; Hong, Bumsik; Hong, Jun; Ahn, Hanjong // Cancer Chemotherapy & Pharmacology;May2015, Vol. 75 Issue 5, p1025 

    Purpose: To assess the efficacy of vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for metastatic renal cell carcinoma (mRCC) patients and to identify predictive factors for increased progression-free survival (PFS) or overall survival (OS). Methods:...

  • Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives. Narayan, Vivek; Haas, Naomi Balzer // International Journal of Nephrology & Renovascular Disease;Mar2016, Vol. 9, p65 

    Background: Axitinib is a next-generation, selective tyrosine kinase inhibitor targeting the vascular endothelial growth factor receptors. It is approved for the treatment of metastatic renal cell carcinoma (mRCC) based on a demonstrated progression-free survival advantage over sorafenib in the...

  • Adjuvant therapy in renal cell carcinoma. Gul, Anita; Rini, Brian I. // Cancer (0008543X);Sep2019, Vol. 125 Issue 17, p2935 

    Localized renal cell carcinoma (RCC) has an associated risk of recurrence after nephrectomy. Several clinical risk models attempt to predict oncologic outcomes based on clinical and pathologic features. In addition, novel gene signatures have been developed to refine risk prediction based on...

  • Axitinib May Work as First-Line Therapy for mRCC. Schieszer, John // Renal & Urology News;Aug2012, Vol. 11 Issue 8, p14 

    The article reports on the use of second-generation inhibitor of vascular endothelial growth factor receptors axitinib as an effective treatment for metastatic renal cell carcinoma (mRCC), according to a study presented the American Society of Clinical Oncology 2012 annual meeting.

  • Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma. Yoshimura, K; Minami, T; Nozawa, M; Uemura, H // British Journal of Cancer;4/2/2013, Vol. 108 Issue 6, p1260 

    Background:It is well known that renal cell carcinoma (RCC) represents one of the most immune-responsive cancers. Although the lack of defined antigens in RCC has hindered more specific vaccine development, research regarding vaccination therapy has been of special interest for the treatment of...

  • The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function. Heine, Annkristin; Held, Stefanie Andrea Erika; Daecke, Solveig Nora; Riethausen, Kati; Kotthoff, Philipp; Flores, Chrystel; Kurts, Christian; Brossart, Peter // PLoS ONE;Jun2015, Vol. 10 Issue 6, p1 

    Inhibitors of VEGF receptor (VEGFR) signaling such as sorafenib and sunitinib that are currently used in the treatment of malignant diseases have been shown to affect immunological responses by inhibition of the function of antigen presenting cells and T lymphocytes. The VEGFR-inhibitor axitinib...

  • The VEGFR Inhibitor Cediranib Improves the Efficacy of Fractionated Radiotherapy in a Colorectal Cancer Xenograft Model. Melsens, Elodie; Verberckmoes, Bert; Rosseel, Natacha; Vanhove, Christian; Descamps, Benedicte; Pattyn, Piet; Ceelen, Wim // European Surgical Research;Apr2017, Vol. 58 Issue 3/4, p95 

    Background/Purpose: Radiotherapy (RT) increases local tumor control in locally advanced rectal cancer, but complete histological response is seen in only a minority of cases. Antiangiogenic therapy has been proposed to improve RT efficacy by "normalizing" the tumor microvasculature. Here, we...

  • Clinical Pharmacology of Axitinib. Chen, Ying; Tortorici, Michael; Garrett, May; Hee, Brian; Klamerus, Karen; Pithavala, Yazdi // Clinical Pharmacokinetics;2013, Vol. 52 Issue 9, p713 

    Axitinib is a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3 that is approved in the US and several other countries for treatment of patients with advanced renal cell carcinoma after failure of one prior systemic therapy. The...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics